Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nightly topical tacrolimus 0.1% ointment for severe vernal keratoconjunctivitis
ChiCTR2000031929Phase 4Completed
- Sponsor
- Self-sponsored
- Start
- Jul 2019
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tacrolimus in Vernal Keratoconjunctivitis (VKC), sponsored by Self-sponsored. Primary endpoints: Symptoms, Conjunctival hyperemia and 3 more. Started Jul 2019; status: completed.
02
Drugs
tacrolimus
03
Conditions
Vernal Keratoconjunctivitis (VKC)
Beyond the preview
Go deeper on ChiCTR2000031929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000031929.